Nanjing/Suzhou, Late August 2026 — Yang Sheng, deputy commissioner of China’s National Medical Products Administration (NMPA), led a delegation to Jiangsu Province to survey innovative drug companies in Nanjing and Suzhou, signaling top-level regulatory support for the province’s biologics and chemical innovation pipeline as Beijing doubles down on whole-chain policies to advance the pharmaceutical sector.

Policy Snapshot

Attribute	Detail
Official	Yang Sheng, NMPA Deputy Commissioner
Location	Nanjing and Suzhou, Jiangsu Province
Participants	NMPA Drug Registration Department; Jiangsu Provincial Medical Products Administration
Focus areas	Biologics; chemical innovative drugs; frontier R&D projects
Key themes	Whole-chain support; regulatory reform; central-local coordination

Key Messages

Yang praised Jiangsu’s achievements in innovative drug development and emphasized that the central party and State Council prioritize biomedical industry growth, with comprehensive policies backing the entire innovation chain. He urged stakeholders to seize development opportunities, concentrate on frontier fields and key technologies, pioneer new tracks and models, accelerate breakthrough product development, and cultivate original first-in-class drugs with high clinical value and strong international competitiveness.

The NMPA will continue deepening evaluation and approval system reforms, optimize central-local coordination mechanisms, enhance regulatory service quality and efficiency, and intensify support for innovative drug R&D to propel high-quality development of the biomedical industry.

Market Impact Analysis

The high-level NMPA visit to Jiangsu—one of China’s densest clusters of biotech and pharmaceutical innovation—sends a strong signal to investors and developers that regulatory capital will continue flowing toward cutting-edge drug modalities. By explicitly calling for “original first-in-class” products with global competitiveness, Yang is elevating the innovation bar beyond fast-follower generics and biosimilars, aligning with Beijing’s strategic goal to reduce dependence on imported novel therapies.

The emphasis on “whole-chain support” and “central-local coordination” suggests forthcoming regulatory refinements that could streamline clinical trial approvals, accelerate priority review pathways, and harmonize provincial-level implementation of national biotech policies. For Jiangsu-based firms, proximity to regulators and demonstrated central government attention may translate into faster feedback loops during the registration process and preferential access to pilot programs for breakthrough therapies.

Forward-Looking Statement

Industry analysts expect the NMPA to unveil concrete measures to optimize the central-local coordination model by year-end, potentially including delegated review authority for mature provincial regulators like Jiangsu and expanded rolling submission pathways for innovative biologics. The focus on “new tracks and models” hints at regulatory sandbox opportunities for cell and gene therapies, radiopharmaceuticals, and AI-enabled drug development platforms. Companies with frontier pipelines in Nanjing and Suzhou are likely to benefit from intensified policy tailwinds, though the call for “internationally competitive” original drugs implies that only assets with global trial footprints and differentiated mechanisms will capture sustained regulatory support.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/ypyw/20260828090800151.html

Beijing, Aug 28, 2026 — China’s National Medical Products Administration (NMPA) suspended sales and use of two batches of Pierre Fabre Medicament’s Encorafenib capsules after a remote inspection found the French drugmaker used an unapproved active pharmaceutical ingredient process change in production and released the product to the Chinese market despite serious quality management deviations.

Regulatory Snapshot

Attribute	Detail
Issuer	National Medical Products Administration (NMPA)
Announcement	2026 No. 81
Target company	Pierre Fabre Medicament (France)
Product	Encorafenib Capsules (国药准字HJ20250082)
Affected batches	5G2T3, 5G2T4
Manufacturing sites	14 Schoolhouse Road, Somerset, NJ, USA; Site Progipharm, rue du Lycée, 45500 Gien, France
Inspection type	Remote inspection
Violation	Unapproved API process change; serious GMP deviation in change control and release review
Legal basis	Drug Administration Law, Article 99; Provisions for Overseas Inspections of Drugs and Medical Devices, Article 30
Effective date	Immediate

Violation Details

The NMPA said its remote review determined that Pierre Fabre had implemented a significant manufacturing process change for the Encorafenib API without obtaining regulatory approval. The company nonetheless used the modified API to produce batches 5G2T3 and 5G2T4, subsequently releasing them for sale in China. Regulators found that the firm’s change-control procedures and batch-release review processes seriously deviated from China’s Good Manufacturing Practice standards (2010 revision) and associated annexes, failing to meet statutory quality system requirements.

Market Impact Analysis

The suspension immediately blocks distribution of the two Encorafenib batches in China, where the BRAF inhibitor is used in oncology protocols, notably for metastatic colorectal cancer with BRAF V600E mutations. For Pierre Fabre, the enforcement action threatens its commercial standing in a key emerging market and raises questions about global change-control governance, given that the API modification appears to have been implemented across manufacturing sites in both the United States and France.

The case marks a significant use of remote inspection authority under Article 99 of the Drug Administration Law, signaling that the NMPA is prepared to invoke market suspension powers based on procedural and quality-system lapses without waiting for confirmed clinical adverse events. The dual-site manufacturing footprint—spanning New Jersey and Gien—suggests the unapproved process change may have broader implications beyond the two flagged batches, potentially triggering portfolio-wide scrutiny.

Forward-Looking Statement

Industry analysts expect Pierre Fabre to face a lengthy remediation process requiring submission of a formal API process change application, completion of supplementary validation studies, and a re-inspection before the suspension can be lifted. The NMPA’s reliance on remote inspection technology to detect the deviation underscores the growing effectiveness of China’s overseas oversight regime, potentially encouraging similar actions against other multinational drugmakers with manufacturing discrepancies. Oncology treatment centers in China may need to source alternative BRAF inhibitor therapies or draw from unaffected inventory batches while the two suspended lots are quarantined and recalled. The case is likely to prompt multinational pharmaceutical companies to audit their global change-control matrices against Chinese GMP requirements more rigorously, particularly for products manufactured across multiple international sites.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260826174000158.html